No Data
No Data
10-Q: Quarterly report
Spectral AI: A Strong Buy on Commercialization Progress and Anticipated Revenue Growth
Spectral AI Hails Progress Towards First Sales and Pre-FDA Clinical Trial | NASDAQ:MDAI
Spectral AI Reiterates FY24 Revenue Guidance Of Approximately $28M, Est $28.2M
Spectral AI Reiterates FY24 Revenue Guidance Of Approximately $28M, Est $28.2M
Spectral AI Q1 2024 GAAP EPS $(0.19) Beats $(0.26) Estimate, Sales $6.326M Miss $7.000M Estimate
Spectral AI (NASDAQ:MDAI) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.26) by 26.92 percent. This is a 29.63 percent increase over losses of $(0.27)
Spectral AI 1Q Loss/Shr 19c >MDAI
Spectral AI 1Q Loss/Shr 19c >MDAI
No Data